Trial Profile

A Randomized, Double-blind, Controlled Study to Assess the Safety, Tolerability, and Pharmacokinetics of RT001 in Patients With Friedreich's Ataxia

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 06 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs RT 001 (Primary)
Indications Friedreich's ataxia
Focus Adverse reactions; First in man; Pharmacokinetics
Sponsors Retrotope

Most Recent Events

18 Apr 2018 Results (n=19) presented in a Retrotope media release.
06 Apr 2018 Results (n=19) assessing safety, tolerability and pharmacokinetics of RT001 in patients with Friedreich's ataxia, were published in the Movement Disorders.
28 Apr 2017 Results presented at the 69th Annual Meeting of the American Academy of Neurology.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com